Companies in #Lung Disease (acquired via Theravance)
Found 1 company operating in this sector.
Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.